Fate Therapeutics Inc. FATE
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2013 · data as of November 13, 2026
Fate Therapeutics Inc. (FATE) is a healthcare company listed in the US with a market value of about $156M. In the twelve months to September 30, 2026 it had revenue of $5M and net income of -$124M, a net margin of -2619.6%.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -27% a year, a 5-year average ROIC of -35%.
About Fate Therapeutics
Fate Therapeutics is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2013. Revenue went from $2M in 2015 to $7M in 2025, growth of about 10.6% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 23% over three years (dilution for shareholders). It spends 1622% of revenue on research and development.
Score: 0.6 / 5
Checks passed
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $5M | $7M | $14M | $64M | $96M | $56M | $31M | $11M | $5M | $4M | $4M |
| Net income | -$124M | -$136M | -$186M | -$161M | -$282M | -$212M | -$173M | -$98M | -$67M | -$43M | -$33M |
| Free cash flow | -$107M | -$112M | -$124M | -$138M | -$284M | -$214M | -$44M | -$91M | -$41M | -$39M | -$30M |
| EPS (diluted) | $-1.03 | $-1.15 | $-1.64 | $-1.64 | $-2.91 | $-2.24 | $-2.10 | $-1.44 | $-1.19 | $-1.02 | $-1.05 |
| Net margin | -2619.6% | -2051.1% | -1366.5% | -253.3% | -292.6% | -379.9% | -551.6% | -919.0% | -1405.0% | -1046.1% | -760.1% |
| ROIC | — | -40.9% | -41.1% | -31.9% | -41.1% | -21.6% | -21.0% | -29.3% | -29.6% | -34.5% | -29.4% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Fate Therapeutics pay a dividend?
Not currently.
Is Fate Therapeutics a good stock to buy?
We do not give buy or sell advice. Fate Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.